Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073210 | 1.00 | PDE4B (0.34) | PDE4BRIPK1HDAC6HDAC4CRHR1 | |
| SCHEMBL25308018 | 0.92 | RIPK1 (0.34) | RIPK1HDAC6CRHR1MRGPRX4HDAC1 | |
| SCHEMBL30468020 | 0.89 | IRAK4 (0.36) | PDE4BGPR6 | |
| SCHEMBL30468056 | 0.89 | IRAK4 (0.36) | PDE4BGPR6 | |
| SCHEMBL25838644 | 0.89 | PDE4B (0.35) | PDE4BRIPK1HDAC6HDAC4JAK2 | |
| SCHEMBL24073575 | 0.89 | PDE4B (0.35) | PDE4BRIPK1HDAC6HDAC4JAK2 | |
| SCHEMBL24073560 | 0.86 | CETP (0.35) | HDAC6CRHR1HDAC1BTKGPR6 | |
| SCHEMBL24073558 | 0.86 | CETP (0.35) | HDAC6CRHR1HDAC1BTKGPR6 | |
| SCHEMBL24073211 | 0.86 | CETP (0.35) | HDAC6CRHR1HDAC1BTKGPR6 | |
| SCHEMBL27418557 | 0.86 | CETP (0.35) | HDAC6CRHR1HDAC1BTKGPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | USP30, UQCRC1, NDUFAF1 | PDE4B 1356/4885RIPK1 2377/4885HDAC6 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.